IDEXX Laboratories, Inc.(IDXX) Stock Research - Grey Stern Research

IDEXX Laboratories, Inc. (IDXX) Stock Analysis

$432.38 (0.06%)

IDXX Financial Performance


Use the table below to view IDEXX Laboratories, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $432.11 -
52 Week Low $398.50 -
52 Week High $583.39 -
Market Cap $35.4 Billion 5/11
Gross Margin 61% 5/11
Profit Margin 24% 2/11
EBITDA margin 21% 5/11
Q3 - 2024 Revenue $975.5 Million 8/11
Q3 - 2024 Earnings $232.8 Million 6/11
Q3 - 2024 Free Cash Flow $192.0 Million 8/11
Trailing 4 Quarters Revenue $3.8 Billion 8/11
Trailing 4 Quarters Earnings $866.2 Million 5/11
Quarterly Earnings Growth 10% 5/11
Annual Earnings Growth -2% 8/11
Quarterly Revenue Growth 7% 2/11
Annual Revenue Growth 3% 2/11
Cash On Hand $308.6 Million 8/11
Short Term Debt $349.1 Million 4/11
Long Term Debt $524.8 Million 9/11

IDEXX Laboratories, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare IDEXX Laboratories, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 40.85 2/11
PS 9.20 3/11
PB 21.87 1/11
PC 114.64 2/11
Liabilities to Equity 1.07 5/11
ROA 0.26 1/11
ROE 0.54 1/11
Current Ratio 1.93 6/11
Quick Ratio 0.18 4/11
Long Term Debt to Equity 0.32 8/11
Debt to Equity 0.54 7/11
Burn Rate -2.48 9/11
Cash to Cap 0.01 9/11
CCR 0.82 8/11
EV to EBITDA 173.17 3/11
EV to Revenue 9.35 2/11

Company Details

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

CEO: Mr. Jonathan Mazelsky

Website: https://www.idexx.com

Address: 1 Idexx Dr Westbrook, MAINE

Exchange: NASDAQ Global Select

Industry: Diagnostics & Research

IDEXX Laboratories, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to IDEXX Laboratories, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Agilent Technologies, Inc. A $40.0 Billion
Danaher Corporation DHR $174.0 Billion
Thermo Fisher Scientific Inc. TMO $204.4 Billion
Illumina, Inc. ILMN $22.3 Billion
IQVIA Holdings Inc. IQV $36.4 Billion
Waters Corporation WAT $23.0 Billion
Charles River Laboratories International, Inc. CRL $10.2 Billion
Mettler-Toledo International Inc. MTD $26.5 Billion
ICON Public Limited Company ICLR $17.6 Billion
Twist Bioscience Corporation TWST $3.0 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
IDXX Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 975.5 Million $232.8 Million
Q2 2024 $ 1.0 Billion $203.3 Million
Q1 2024 $ 964.1 Million $235.6 Million
Q4 2023 $ 901.6 Million $194.5 Million
Q3 2023 $ 915.5 Million $212.2 Million
Q2 2023 $ 943.6 Million $224.2 Million
Q1 2023 $ 900.2 Million $214.1 Million
Q4 2022 $ 828.6 Million $172.2 Million

View All

IDXX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $308.6 Million $3.4 Billion $873.9 Million $1.6 Billion
Q2 2024 $401.6 Million $3.4 Billion $944.9 Million $1.6 Billion
Q1 2024 $397.4 Million $3.4 Billion $1.1 Billion $1.6 Billion
Q4 2023 $453.9 Million $3.3 Billion $697.9 Million $1.5 Billion
Q3 2023 $331.7 Million $3.1 Billion $1.0 Billion $1.3 Billion
Q2 2023 $132.8 Million $2.9 Billion $1.0 Billion $1.1 Billion
Q1 2023 $111.4 Million $2.8 Billion $1.2 Billion $841.1 Million
Q4 2022 $112.5 Million $2.7 Billion $1.3 Billion $608.7 Million

View All

IDXX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $192.0 Million -$28.1 Million -$93.0 Million
Q2 2024 $215.0 Million -$33.3 Million $215.0 Million
Q1 2024 $168.3 Million -$30.3 Million -$56.5 Million
Q4 2023 $0 $0 $0
Q3 2023 $238.3 Million -$34.1 Million $198.9 Million
Q2 2023 $172.8 Million -$27.5 Million $21.5 Million
Q1 2023 $144.4 Million -$39.5 Million -$1.2 Million
Q4 2022 $134.2 Million -$39.2 Million $13.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions